End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10 CNY | +5.26% | +26.90% | +6.84% |
04-28 | Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-19 | Fushine Pharma's Unit Gets Nod for Tazobactam Sodium | MT |
Sales 2022 | 1.65B 228M 311M | Sales 2023 | 1.61B 223M 304M | Capitalization | 5.04B 697M 952M |
---|---|---|---|---|---|
Net income 2022 | -141M -19.5M -26.62M | Net income 2023 | -201M -27.79M -37.94M | EV / Sales 2022 | 4.55 x |
Net Debt 2022 | 390M 53.92M 73.61M | Net Debt 2023 | 895M 124M 169M | EV / Sales 2023 | 3.69 x |
P/E ratio 2022 |
-50.8
x | P/E ratio 2023 |
-25.3
x | Employees | 2,179 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.76% |
1 day | +5.26% | ||
1 week | +26.90% | ||
Current month | +7.41% | ||
1 month | +6.84% | ||
3 months | +22.85% | ||
6 months | -2.82% | ||
Current year | +6.84% |
Managers | Title | Age | Since |
---|---|---|---|
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Guang Yang
DFI | Director of Finance/CFO | 37 | 08-12-31 |
Rong Wu Cheng
BRD | Director/Board Member | 55 | 04-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yan Li
BRD | Director/Board Member | 67 | 15-06-30 |
Jian Hua Bao
CEO | Chief Executive Officer | 47 | 12-07-31 |
Wei Dong
BRD | Director/Board Member | 46 | 12-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-28 | 10 | +5.26% | 13 770 630 |
24-04-26 | 9.5 | +5.32% | 13,177,050 |
24-04-25 | 9.02 | +4.28% | 7,207,900 |
24-04-24 | 8.65 | +6.00% | 7,075,232 |
24-04-23 | 8.16 | +1.37% | 3,820,100 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.84% | 706M | |
+25.98% | 661B | |
+26.74% | 566B | |
-6.76% | 352B | |
+19.19% | 332B | |
+3.18% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.42% | 145B |
- Stock Market
- Equities
- 300497 Stock